One-Stop Complete Solution for γδ T Cell Culture
Release Date:
2025-10-20 15:51
Overview of the Biological Characteristics of γδ T Cells
γδ T cells Immune checkpoint inhibitor therapy, as an emerging immunotherapy, has become a new research hotspot due to its unique anti-tumor advantages. γδ T cells exert their anti-tumor effects primarily by secreting pro-apoptotic molecules and inflammatory cytokines, or through TCR-dependent mechanisms. Numerous clinical studies have demonstrated that γδ T-cell–based immunotherapy exhibits good tolerability and efficacy.
γδ T cells primarily modulate anti-tumor responses by producing pro-apoptotic factors and cytokines, as well as through TCR-dependent mechanisms. In γδ T-cell–based cancer immunotherapy, the main challenges are the limited expansion of γδ T cells in vitro and the lack of established, robust protocols for their ex vivo expansion. Currently, the most effective approach for expanding γδ T cells involves the use of phosphorylated antigens or anti-γδ TCR antibodies. A simple zoledronic acid–based amplification system yields a low amplification fold and exhibits weak sustained amplification capacity in both animal and human models.
The main antitumor mechanisms of γδ T cells are as follows: 1) direct killing of tumor cells via NK cell receptors; 2) induction of tumor cell apoptosis through apoptosis-related ligands (TRAIL/FASL); 3) killing of tumor cells by secreting granzyme/perforin; and 4) through ADCC effect Kill tumor cells. 5. Act as antigen-presenting cells to activate αβ T cells 6. Promote the maturation of dendritic cells. 7. Enhance antibody production by B cells, thereby boosting humoral immune responses. 8. Activate natural killer (NK) cells through the expression of 4-1BBL.
Images sourced from the internet; please contact us for removal if there is any infringement.
The safety and non- Major Histocompatibility Complex Its restrictive nature, coupled with extensive experimental evidence demonstrating favorable prognostic outcomes and therapeutic value in cancer treatment, underscores the potential of γδ T cells. By sensing stress signals uniquely expressed by cancer cells while sparing healthy cells, γδ T cells exhibit minimal adverse effects, thereby offering broader clinical application prospects. The establishment of standardized γδ T cell populations via clinically established, highly efficient, and safe ex vivo expansion protocols has become an essential step in the treatment of malignant tumors; consequently, the development of an effective and safe ex vivo expansion system for γδ T cells represents a critical challenge that urgently needs to be addressed.
Shanghai Hycells Biotechnology is a high-tech enterprise specializing in research on primary immune cells and stem cells. The company has established an integrated technology platform dedicated to providing customers with end-to-end, comprehensive solutions covering both immune cells and mesenchymal stem cells. It offers professional support across the entire γδT cell culture workflow—ranging from compliant and ethically sound pre-screening and collection services for γδT super-donors to the integration of high-performance HiXpan Registered trademark A one-stop culture system comprising a serum-free γδT cell culture kit and Cell Feeder transwell cell culture flasks, comprehensively empowering innovation and clinical translation in cell therapy.
Pre-screening of γδT super donors
Step 1
Receive blood samples, isolate PBMCs, and cryopreserve them.
Step 2
Screen frozen PBMCs for the proportion of γδ T cells (using Vδ2+ as a marker) and select batches with a relatively high proportion (approximately 5%).
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board